These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 29414039)

  • 1. Untying the knot of transcription factor druggability: Molecular modeling study of FOXM1 inhibitors.
    Tabatabaei-Dakhili SA; Aguayo-Ortiz R; Domínguez L; Velázquez-Martínez CA
    J Mol Graph Model; 2018 Mar; 80():197-210. PubMed ID: 29414039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanism of Forkhead box M1 inhibition by thiostrepton in breast cancer cells.
    Kongsema M; Wongkhieo S; Khongkow M; Lam EW; Boonnoy P; Vongsangnak W; Wong-Ekkabut J
    Oncol Rep; 2019 Sep; 42(3):953-962. PubMed ID: 31322278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SP1-independent inhibition of FOXM1 by modified thiazolidinediones.
    Tabatabaei Dakhili SA; Pérez DJ; Gopal K; Haque M; Ussher JR; Kashfi K; Velázquez-Martínez CA
    Eur J Med Chem; 2021 Jan; 209():112902. PubMed ID: 33069434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The transcription factor FOXM1 is a cellular target of the natural product thiostrepton.
    Hegde NS; Sanders DA; Rodriguez R; Balasubramanian S
    Nat Chem; 2011 Aug; 3(9):725-31. PubMed ID: 21860463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A structure-activity relationship study of Forkhead Domain Inhibitors (FDI): The importance of halogen binding interactions.
    Tabatabaei Dakhili SA; Pérez DJ; Gopal K; Tabatabaei Dakhili SY; Ussher JR; Velázquez-Martínez CA
    Bioorg Chem; 2019 Dec; 93():103269. PubMed ID: 31654840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico investigation of FOXM1 binding and novel inhibitors in epithelial ovarian cancer.
    Chen Y; Ruben EA; Rajadas J; Teng NNH
    Bioorg Med Chem; 2015 Aug; 23(15):4576-4582. PubMed ID: 26164623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FoxM1 inhibitors as potential anticancer drugs.
    Gartel AL
    Expert Opin Ther Targets; 2008 Jun; 12(6):663-5. PubMed ID: 18479213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FoxM1 by thiostrepton inhibits growth and induces apoptosis of laryngeal squamous cell carcinoma.
    Jiang L; Wu X; Wang P; Wen T; Yu C; Wei L; Chen H
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):971-81. PubMed ID: 25391371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting of mutant p53-induced FoxM1 with thiostrepton induces cytotoxicity and enhances carboplatin sensitivity in cancer cells.
    Zhang X; Cheng L; Minn K; Madan R; Godwin AK; Shridhar V; Chien J
    Oncotarget; 2014 Nov; 5(22):11365-80. PubMed ID: 25426548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A drug repurposing study identifies novel FOXM1 inhibitors with in vitro activity against breast cancer cells.
    Abusharkh KAN; Comert Onder F; Çınar V; Hamurcu Z; Ozpolat B; Ay M
    Med Oncol; 2024 Jun; 41(8):188. PubMed ID: 38918225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FoxM1 is a general target for proteasome inhibitors.
    Bhat UG; Halasi M; Gartel AL
    PLoS One; 2009 Aug; 4(8):e6593. PubMed ID: 19672316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of forkhead box M1 (FoxM1) expression and antitumour effect of FoxM1 inhibition in melanoma.
    Ito T; Kohashi K; Yamada Y; Maekawa A; Kuda M; Furue M; Oda Y
    Histopathology; 2016 Jul; 69(1):63-71. PubMed ID: 26619071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of FOXM1 by thiostrepton sensitizes medulloblastoma to the effects of chemotherapy.
    Lin J; Zheng Y; Chen K; Huang Z; Wu X; Zhang N
    Oncol Rep; 2013 Oct; 30(4):1739-44. PubMed ID: 23912794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new target for proteasome inhibitors: FoxM1.
    Gartel AL
    Expert Opin Investig Drugs; 2010 Feb; 19(2):235-42. PubMed ID: 20074015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Forkhead box protein M1 by thiostrepton increases chemosensitivity to doxorubicin in T-cell acute lymphoblastic leukemia.
    Wang JY; Jia XH; Xing HY; Li YJ; Fan WW; Li N; Xie SY
    Mol Med Rep; 2015 Jul; 12(1):1457-64. PubMed ID: 25760224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based virtual screening towards the discovery of novel FOXM1 inhibitors.
    Xie ZS; Zhou ZY; Sun LQ; Yi H; Xue ST; Li ZR
    Future Med Chem; 2022 Feb; 14(4):207-219. PubMed ID: 34809496
    [No Abstract]   [Full Text] [Related]  

  • 18. Effects of metformin on FOXM1 expression and on the biological behavior of acute leukemia cell lines.
    Zhang B; Liu LL; Mao X; Zhang DH
    Mol Med Rep; 2014 Dec; 10(6):3193-8. PubMed ID: 25310131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FoxM1 inhibits proliferation, invasion and migration of nasopharyngeal carcinoma through the epithelial‑to-mesenchymal transition pathway.
    Yu C; Chen L; Yie L; Wei L; Wen T; Liu Y; Chen H
    Oncol Rep; 2015 May; 33(5):2402-10. PubMed ID: 25738652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Foxm1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
    Westhoff GL; Chen Y; Teng NNH
    Int J Gynecol Cancer; 2017 Jun; 27(5):887-894. PubMed ID: 28498253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.